Electrochemotherapy of unresectable cutaneous tumours with reduced dosages of intravenous bleomycin: analysis of 57 patients from the International Network for Sharing Practices of Electrochemotherapy registry

Rotunno, Roberta; Campana, Luca Giovanni; Quaglino, Pietro; Terlizzi, Francesca de; Kunte, Christian; Odili, Joy; Gehl, Julie; Ribero, Simone; Liew, Se Hwang; Marconato, R; Brizio, Matteo; Curatolo, P.

doi:10.1111/jdv.14708

Cited by 47 publications

(51 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Preliminary results demonstrated comparable effectiveness in nonmelanoma skin metastases in head and neck cancer, 116 which was also confirmed for other types of skin tumors, that is, melanoma, breast cancer, and Kaposi's sarcoma. 117 FIG. 2.…”

Section: Clinical Studies In Human Oncologymentioning

confidence: 99%

Recent Advances in Electrochemotherapy

Čemažar

Serša

2019

Bioelectricity

View full text Add to dashboard Cite

Electrochemotherapy is gaining recognition as an effective local therapy that uses systemically or intratumorally injected bleomycin or cisplatin with electroporation as a delivery system that brings drugs into the cells to exert their cytotoxic effects. Preclinical work is still ongoing, testing new drugs, seeking the best treatment combination with other treatment modalities, and exploring new sets of pulses for effective tissue electroporation. The applications of electrochemotherapy are being fully exploited in veterinary oncology, where electrochemotherapy, because of its simple execution, has a relatively good cost-benefit ratio and is used in the treatment of cutaneous tumors. In human oncology, electrochemotherapy is fully recognized as a local therapy for cutaneous tumors and metastases. Its effectiveness is being explored in combination with immunomodulatory drugs. However, the development of electrochemotherapy is directed into the treatment of deepseated tumors with a percutaneous approach. Because of the vast number of reports, this review discusses the articles published in the past 5 years.

show abstract

Section: Clinical Studies In Human Oncologymentioning

confidence: 99%

Recent Advances in Electrochemotherapy

Čemažar

Serša

2019

Bioelectricity

View full text Add to dashboard Cite

show abstract

“…Noteworthy, the 2018 ESOPE guidelines have extended the maximum duration of the procedure, thus allowing for the treatment of patients with more widespread tumors. Conversely, the BLM dose can be safely de-escalated without affecting treatment efficacy [92][93][94] . In this regard, clinicians should be acquainted with use of chemotherapy, and cognizant of its possible, although rare, side effects.…”

Section: Discussionmentioning

confidence: 99%

“…bolus infusion of 15,0 0 0 IU/m 2 . Recent pharmacokinetic studies indicate a slow elimination rate in elderly patients and support a reduction of dosages or, alternatively, an extension of the therapeutic window for pulse application, while preserving treatment efficacy [92][93][94] . BLM is the preferred drug in ECT because of its favorable toxicity profile.…”

Section: Bleomycinmentioning

confidence: 99%

“…In the most frequently applied modality (ie, general anesthesia/sedation and i.v. BLM), when the patient is properly anesthetized, a bolus of BLM is followed, after 8 minutes, by the application of electric pulses over a 40-minute interval [92][93][94] . At present, there is no supporting information as to the optimal number of ECT sessions and interval between them.…”

Section: Standard Operating Proceduresmentioning

confidence: 99%

See 1 more Smart Citation

Electrochemotherapy of superficial tumors – Current status:

Campana

Miklavčič

Bertino

et al. 2019

Seminars in Oncology

View full text Add to dashboard Cite

“…To perform this study ESOPE guidelines were followed. 8,14 The objective response ranges from 81% to 100% in several studies with a complete response from 0% to 70%. 1 The great variability of the response is linked to the tumor type, its size, and the previous therapy used for the ECT-treated cancer.…”

Section: T a B L Ementioning

confidence: 99%

The use of cisplatin electrochemotherapy in nonmelanoma skin cancers: A single‐center study

Giorgi

Scarfì

Saqer

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Electrochemotherapy (ECT) is a well‐known nonconventional skin cancer ablative method that was shown to be safe and effective for treating both locoregional disease spreading and disseminated cutaneous and subcutaneous lesions from different types of cancer. The most common medications used are bleomycin and cisplatin. In the last years many studies were performed on ECT, lead it to be a valid therapeutic option in many international guidelines. Nevertheless, there are still no clear indications regarding timing of its use. The main aim of this study was first to assess the safety and effectiveness of intralesional cisplatin ECT for treating different types of nonmelanoma skin cancer in a group of eligible patients. The second endpoint was to assess patients' tolerability and symptoms improvement through the treatment. A single‐center prospective study was performed. Patients with squamous cell carcinoma, basal cell carcinoma, or skin metastases were selected during 1 month. The ideal setting was the presence of two or three lesions with a maximum diameter of 2 cm. Both primary, recurrent, and metastatic lesions were included. Before and 8 weeks after treatment, all patients were evaluated to assess the number, measurement, and anatomical site of skin lesions using photography and metric notation. The medical device for membrane electroporation was the CLINIPORATOR EPS02 model. The cisplatin concentration was at least 1 mg/mL. The dose for each single lesion was calculated based on its volume, as is the standard procedure for ECT. Local or systemic adverse events and changes in symptoms were evaluated with a questionnaire based on a visual analog scale that was administrated before and after ECT. Eight patients with a total of 18 lesions underwent the procedure (six men and two women). Four out of eight (50%) patients had a complete response to the treatment. However, all eight patients had an overall tumor response (100%), experiencing an improvement in symptoms including less pain and bleeding from the tumor. Our study clearly show that ECT with intralesional cisplatin is a valuable and safety procedure for nonmelanoma skin cancer and cutaneous tumor metastasis. ECT with cisplatin was able to achieve a good local disease control leading to complete response in an half of cases. The results were stable after 1 year of follow‐up. The outer ear area displayed a really good response, due to both ear's anatomical configuration and intralesional cisplatin pharmacological characteristics.

show abstract

Electrochemotherapy of unresectable cutaneous tumours with reduced dosages of intravenous bleomycin: analysis of 57 patients from the International Network for Sharing Practices of Electrochemotherapy registry

Cited by 47 publications

References 30 publications

Recent Advances in Electrochemotherapy

Recent Advances in Electrochemotherapy

Electrochemotherapy of superficial tumors – Current status:

The use of cisplatin electrochemotherapy in nonmelanoma skin cancers: A single‐center study

Contact Info

Product

Resources

About